ERBA Diagnostics, Inc. 8-K 2006
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 or 15(d) of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report
April 19, 2006
(Date of earliest event reported)
IVAX Diagnostics, Inc.
(Exact name of registrant as specified in its charter)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On April 19, 2006, Dr. Phillip Frost, Mr. Neil Flanzraich, and Dr. Jane Hsiao resigned from IVAX Diagnostics, Inc.s Board of Directors (the Board), and Dr. Itzhak Krinsky, Mark Durand and Richard Egosi were appointed to the Board to fill the vacancies and to serve until the next annual meeting of stockholders.
Dr. Krinsky, who is the Corporate Vice President Business Development of Teva Pharmaceutical Industries Limited, has succeeded Dr. Frost as the non-executive Chairman of the Board. Mr. Durand is the Chief Financial Officer and Senior Vice PresidentFinance and Business Development for Teva North America. Mr. Egosi is the Senior Vice President and General Counsel for Teva North America.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 20, 2006